Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 May 5:17:1051-1067.
doi: 10.2147/COPD.S347588. eCollection 2022.

Efficacy of ICS versus Non-ICS Combination Therapy in COPD: A Meta-Analysis of Randomised Controlled Trials

Yanling Ding #  1 , Lina Sun #  1 , Ying Wang  1 , Jing Zhang  1 , Yahong Chen  1
Affiliations
Meta-Analysis

Efficacy of ICS versus Non-ICS Combination Therapy in COPD: A Meta-Analysis of Randomised Controlled Trials

Yanling Ding et al. Int J Chron Obstruct Pulmon Dis. .

Abstract

Background: Several large randomized clinical trials (RCTs) have assessed the efficacy and safety of inhaled corticosteroid (ICS) combination regimens versus non-ICS therapy in patients with chronic obstructive pulmonary disease (COPD) at increased risk of exacerbation risk with mixed results.

Methods: We performed a systematic literature review and meta-analysis of RCTs comparing the effect of ICS-containing combination therapy and non-ICS regimen in patients with COPD.

Results: A total of 54 RCTs (N = 57,333) reported treatment effects on various outcomes and were eligible for inclusion. Overall, the number of patients experiencing moderate/severe exacerbations was significantly lower for ICS-containing combination therapy versus non-ICS therapy (RR: 0.86 [95% CI: 0.80-0.93]). The annual rate of exacerbations was also significantly reduced by 22% (0.78 [0.72-0.86]) with ICS-containing versus non-ICS therapy. The annual rate of exacerbations requiring hospitalisation was reduced by 31% versus non-ICS therapy (0.69 [0.54-0.88]); similar reduction was observed for exacerbations requiring oral steroids (0.69 [0.66-0.73]). Overall, the effect on trough FEV1 was comparable between ICS-containing and non-ICS therapies (follow-up: 6-52 weeks); however, a significant improvement in lung function (trough FEV1) was observed for ICS/LABA versus LABA (MD: +0.04 L [0.03-0.05]) and ICS/LABA/LAMA versus LAMA (MD: +0.09 L [0.05-0.13]) regimens. In addition, a significant improvement in QoL was observed with ICS-containing versus non-ICS therapy (MD in SGRQ score: -0.90 [-1.50, -0.31]).

Conclusion: This meta-analysis demonstrated that a wide range of patients with COPD could benefit from dual and triple ICS-containing therapy.

Keywords: chronic obstructive pulmonary disease; dual therapy; exacerbation; inhaled corticosteroid; meta-analysis; triple therapy.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Preferred Reporting Items for Systematic Reviews and Meta-Analyses protocols (PRISMA-P) flow diagram for the identification of studies included in the meta-analysis concerning the impact of benefit from dual and triple ICS-containing therapy versus non-ICS therapy in chronic obstructive pulmonary disease (COPD). Three publications found by hand search were included in the meta-analysis.
Figure 2
Figure 2
Effects of treatment on the change in trough FEV1 (pre-dose) by therapeutic regimen.
Figure 3
Figure 3
Effects of treatment on the number of patients experiencing COPD exacerbations by therapeutic regimen.
Figure 4
Figure 4
Effects of treatment on the annual rate of COPD exacerbations by therapeutic regimen.
See this image and copyright information in PMC

Comment in

References

    1. GOLD-2020-REPORT-ver1.0wms.pdf [Internet]. [cited December 9, 2021]. Available from: https://goldcopd.org/wp-content/uploads/2019/11/GOLD-2020-REPORT-ver1.0w.... Accessed April 19, 2022.
    1. Anzueto A. Impact of exacerbations on COPD. Eur Respir Rev. 2010;19(116):113–118. doi: 10.1183/09059180.00002610 - DOI - PMC - PubMed
    1. May SM, Li JTC. Burden of chronic obstructive pulmonary disease: healthcare costs and beyond. Allergy Asthma Proc. 2015;36(1):4–10. doi: 10.2500/aap.2015.36.3812 - DOI - PMC - PubMed
    1. Halpin DM, Miravitlles M, Metzdorf N, Celli B. Impact and prevention of severe exacerbations of COPD: a review of the evidence. Int J Chron Obstruct Pulmon Dis. 2017;12:2891–2908. doi: 10.2147/COPD.S139470 - DOI - PMC - PubMed
    1. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study - PubMed [Internet]. [cited December 9, 2021]. Available from: https://pubmed.ncbi.nlm.nih.gov/24321804/. Accessed April 19, 2022. - PubMed

MeSH terms

Substances